Skip to content
2000
image of Apatinib and Adebrelimab Exhibit Synergistic Antitumor effects in Small Cell Lung Cancer: An In Vitro Study

Abstract

Background

Small cell lung cancer (SCLC) is a highly aggressive malignancy. This study investigated whether Apatinib (Apa) combined with Adebrelimab (Ade) exerted synergistic effects against SCLC.

Methods

Half-maximal inhibitory concentration (IC) value of Apa and Ade, administered alone or in combination, was determined in H446 and H1436 cells using cell counting kit-8 (CCK-8) assays. Synergistic effects were quantified by calculating fractional inhibitory concentration (FIC) indices. Cell proliferation, migration, and invasion were assessed by CCK-8, wound healing, and Transwell assays, respectively. After co-culture with CD8+ T cells, PD-L1 expression and CD8+ IFN-γ+ T cell proportion were measured by flow cytometry. TGF-β secretion and LDH release were detected using ELISA and LDH assay, respectively; the protein level of VEGFR2 and STAT3 was analyzed by western blot.

Results

Apa alone exhibited IC values of 20.03 μM (H446) and 35.50 μM (H1436), while Ade alone exhibited 5.789 μM and 6.959 μM, respectively. The sum FIC values were 0.681 for H446 cells and 0.973 for H1436 cells. Compared with either monotherapy, combined treatment more effectively reduced cell viability, migration, and invasion. In co-culture experiments, the combination further suppressed PD-L1 expression and TGF-β secretion, increased CD8+ IFN-γ+ T cells and LDH release, and downregulated VEGFR2, p-STAT3, and PD-L1 protein levels.

Discussion

This study demonstrated that the combination of Apa and Ade exerted synergistic anti-tumor effects against SCLC . Further investigation, including animal studies and clinical trials, is warranted to evaluate the efficacy and long-term safety of this combination therapy.

Conclusion

In summary, the combination of Apa and Ade represented a promising innovative therapeutic strategy for SCLC.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673478917260414214002
2026-04-30
2026-05-19

  • From This Site

    /content/journals/cmc/10.2174/0109298673478917260414214002
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Yin X. Li Y. Wang H. Jia T. Wang E. Luo Y. Wei Y. Qin Z. Ma X. Small cell lung cancer transformation: From pathogenesis to treatment. Semin. Cancer Biol. 2022 86 Pt 2 595 606 10.1016/j.semcancer.2022.03.006 35276343
    [Google Scholar]
  2. Mondelo-Macía P. García-González J. León-Mateos L. Castillo-García A. López-López R. Muinelo-Romay L. Díaz-Peña R. Current status and future perspectives of liquid biopsy in small cell lung cancer. Biomedicines 2021 9 1 48 10.3390/biomedicines9010048 33430290
    [Google Scholar]
  3. Meijer J.J. Leonetti A. Airò G. Tiseo M. Rolfo C. Giovannetti E. Vahabi M. Small cell lung cancer: Novel treatments beyond immunotherapy. Semin. Cancer Biol. 2022 86 Pt 2 376 385 10.1016/j.semcancer.2022.05.004 35568295
    [Google Scholar]
  4. Qian X.J. Wang J.W. Liu J.B. Yu X. The mediating role of miR-451/ETV4/MMP13 signaling axis on epithelialmesenchymal transition in promoting non-small cell lung cancer progression. Curr. Mol. Pharmacol. 2023 17 e210723218988 10.2174/1874467217666230721123554 37489792
    [Google Scholar]
  5. Lahiri A. Maji A. Potdar P.D. Singh N. Parikh P. Bisht B. Mukherjee A. Paul M.K. Lung cancer immunotherapy: Progress, pitfalls, and promises. Mol. Cancer 2023 22 1 40 10.1186/s12943‑023‑01740‑y 36810079
    [Google Scholar]
  6. Tang S. Qin C. Hu H. Liu T. He Y. Guo H. Yan H. Zhang J. Tang S. Zhou H. Immune checkpoint inhibitors in non-small cell lung cancer: Progress, challenges, and prospects. Cells 2022 11 3 320 10.3390/cells11030320 35159131
    [Google Scholar]
  7. Petrillo L.A. Shimer S.E. Zhou A.Z. Sommer R.K. Feldman J.E. Hsu K.E. Greer J.A. Traeger L.N. Temel J.S. Prognostic communication about lung cancer in the precision oncology era: A multiple-perspective qualitative study. Cancer 2022 128 16 3120 3128 10.1002/cncr.34369 35731234
    [Google Scholar]
  8. Cheng W. Kang K. Zhao A. Wu Y. Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer. J. Hematol. Oncol. 2024 17 1 54 10.1186/s13045‑024‑01581‑2 39068460
    [Google Scholar]
  9. Lu X. Ma L. Yin X. Ji H. Qian Y. Zhong S. Yan A. Zhang Y. The impact of tobacco exposure on tumor microenvironment and prognosis in lung adenocarcinoma by integrative analysis of multi-omics data. Int. Immunopharmacol. 2021 101 Pt B 108253 10.1016/j.intimp.2021.108253 34700112
    [Google Scholar]
  10. Tao Z. Kuai X. Wang G. Liu S. Liu K. Zhang H. Xia S. Zhu H. Combination of chemotherapy and immune checkpoint therapy by the immunoconjugates-based nanocomplexes synergistically improves therapeutic efficacy in SCLC. Drug Deliv. 2022 29 1 1571 1581 10.1080/10717544.2022.2039803 35612299
    [Google Scholar]
  11. Ran X. Wu B.X. Vidhyasagar V. Song L. Zhang X. Ladak R.J. Teng M. Ba-alawi W. Philip V. He H.H. Sonenberg N. Lok B.H. PARP inhibitor radiosensitization enhances anti-PD-L1 immunotherapy through stabilizing chemokine mRNA in small cell lung cancer. Nat. Commun. 2025 16 1 2166 10.1038/s41467‑025‑57257‑z 40038278
    [Google Scholar]
  12. Rudin C.M. Awad M.M. Navarro A. Gottfried M. Peters S. Csőszi T. Cheema P.K. Rodriguez-Abreu D. Wollner M. Yang J.C.H. Mazieres J. Orlandi F.J. Luft A. Gümüş M. Kato T. Kalemkerian G.P. Luo Y. Ebiana V. Pietanza M.C. Kim H.R. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: Randomized, double-blind, phase III KEYNOTE-604 study. J. Clin. Oncol. 2020 38 21 2369 2379 10.1200/JCO.20.00793 32468956
    [Google Scholar]
  13. Paz-Ares L. Dvorkin M. Chen Y. Reinmuth N. Hotta K. Trukhin D. Statsenko G. Hochmair M.J. Özgüroğlu M. Ji J.H. Voitko O. Poltoratskiy A. Ponce S. Verderame F. Havel L. Bondarenko I. Kazarnowicz A. Losonczy G. Conev N.V. Armstrong J. Byrne N. Shire N. Jiang H. Goldman J.W. Batagelj E. Casarini I. Pastor A.V. Sena S.N. Zarba J.J. Burghuber O. Hartl S. Hochmair M.J. Lamprecht B. Studnicka M. Alberto Schlittler L. Augusto Martinelli de Oliveira F. Calabrich A. Colagiovanni Girotto G. Dos Reis P. Fausto Nino Gorini C. Rafael Martins De Marchi P. Serodio da Rocha Baldotto C. Sette C. Zukin M. Conev N.V. Dudov A. Ilieva R. Koynov K. Krasteva R. Tonev I. Valev S. Venkova V. Bi M. Chen C. Chen Y. Chen Z. Fang J. Feng J. Han Z. Hu J. Hu Y. Li W. Liang Z. Lin Z. Ma R. Ma S. Nan K. Shu Y. Wang K. Wang M. Wu G. Yang N. Yang Z. Zhang H. Zhang W. Zhao J. Zhao Y. Zhou C. Zhou J. Zhou X. Havel L. Kolek V. Koubkova L. Roubec J. Skrickova J. Zemanova M. Chouaid C. Hilgers W. Lena H. Moro-Sibilot D. Robinet G. Souquet P-J. Alt J. Bischoff H. Grohe C. Laack E. Lang S. Panse J. Reinmuth N. Schulz C. Bogos K. Csánky E. Fülöp A. Horváth Z. Kósa J. Laczó I. Losonczy G. Pajkos G. Pápai Z. Pápai Székely Z. Sárosi V. Somfay A. Somogyiné Ezer É. Telekes A. Bar J. Gottfried M. Heching N.I. Zer Kuch A. Bartolucci R. Bettini A.C. Delmonte A. Garassino M.C. Minelli M. Roila F. Verderame F. Atagi S. Azuma K. Goto H. Goto K. Hara Y. Hayashi H. Hida T. Hotta K. Kanazawa K. Kanda S. Kim Y.H. Kuyama S. Maeda T. Morise M. Nakahara Y. Nishio M. Nogami N. Okamoto I. Saito H. Shinoda M. Umemura S. Yoshida T. Claessens N. Cornelissen R. Heniks L. Hiltermann J. Smit E. Staal van den Brekel A. Kazarnowicz A. Kowalski D. Mańdziuk S. Mróz R. Wojtukiewicz M. Ciuleanu T. Ganea D. Ungureanu A. Dvorkin M. Luft A. Moiseenko V. Poltoratskiy A. Sakaeva D. Smolin A. Statsenko G. Vasilyev A. Vladimirova L. Anasina I. Chovanec J. Demo P. Godal R. Kasan P. Stresko M. Urda M. Cho E.K. Ji J.H. Kim J-H. Kim S-W. Lee G-W. Lee J-S. Lee K.H. Lee K.H. Lee Y.G. Amelia Insa Molla M. Domine Gomez M. Ignacio Delgado Mingorance J. Isla Casado D. Lopez Brea M. Majem Tarruella M. Morán Bueno T. Navarro Mendivil A. Paz-Ares Rodríguez L. Ponce Aix S. Rosario Garcia Campelo M. Chang G-C. Chen Y-H. Chiu C-H. Hsia T-C. Lee K-Y. Li C-T. Wang C-C. Wei Y-F. Wu S-Y. Alacacıoğlu A. Çiçin I. Demirkazik A. Erman M. Göksel T. Özgüroğlu M. Adamchuk H. Bondarenko I. Kolesnik O. Kryzhanivska A. Ostapenko Y. Shevnia S. Shparyk Y. Trukhin D. Ursol G. Voitko N. Voitko O. Vynnychenko I. Babu S. Chen Y. Chiang A. Chua W. Dakhil S. Dowlati A. Goldman J.W. Haque B. Jamil R. Knoble J. Lakhanpal S. Mi K. Nikolinakos P. Powell S. Ross H. Schaefer E. Schneider J. Spahr J. Spigel D. Stilwill J. Sumey C. Williamson M. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial. Lancet 2019 394 10212 1929 1939 10.1016/S0140‑6736(19)32222‑6 31590988
    [Google Scholar]
  14. Mansfield A.S. Każarnowicz A. Karaseva N. Sánchez A. De Boer R. Andric Z. Reck M. Atagi S. Lee J.S. Garassino M. Liu S.V. Horn L. Wen X. Quach C. Yu W. Kabbinavar F. Lam S. Morris S. Califano R. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): A randomized phase I/III trial. Ann. Oncol. 2020 31 2 310 317 10.1016/j.annonc.2019.10.021 31959349
    [Google Scholar]
  15. Yang H. Yang L. Liu Y. Wang L. Adebrelimab in small cell lung cancer: From current advances to emerging combination strategy and challenge. Biologics 2025 19 365 377 40475251
    [Google Scholar]
  16. Wang J. Zhou C. Yao W. Wang Q. Min X. Chen G. Xu X. Li X. Xu F. Fang Y. Yang R. Yu G. Gong Y. Zhao J. Fan Y. Liu Q. Cao L. Yao Y. Liu Y. Li X. Wu J. He Z. Lu K. Jiang L. Hu C. Zhao W. Zhang B. Shi W. Zhang X. Cheng Y. Cheng Y. Wang J. Zhou C. Yao W. Wang Q. Min X. Chen G. Xu X. Li X. Xu F. Fang Y. Yang R. Yu G. Gong Y. Zhao J. Fan Y. Liu Q. Cao L. Yao Y. Liu Y. Li X. Wu J. He Z. Lu K. Jiang L. Hu C. Zhao W. Yu H. Zhao J. Wu G. Huang D. Chen C. Ding C. Zhang B. Wang X. Luo H. Li B. Zhang S. Lu H. Shi M. Chen X. Guo Y. Liu H. Liu J. Gao H. Hu S. Hong Q. Li Q. Zhang B. Shi W. Zhang X. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022 23 6 739 747 10.1016/S1470‑2045(22)00224‑8 35576956
    [Google Scholar]
  17. Chen D. Zou B. Li B. Gao A. Huang W. Shao Q. Meng X. Zhang P. Tang X. Hu X. Zhang Y. Guo J. Zhao C. Yuan J. Li Q. Zhu C. Yu J. Wang L. Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small–cell lung cancer (ES-SCLC): A phase II trial. EClinicalMedicine 2024 75 102795 10.1016/j.eclinm.2024.102795 39252865
    [Google Scholar]
  18. Liu Y. Chen T. Shen D. Zhang W. Wang C. Jiang J. Zeng D. Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: A case series and literature review. J. Int. Med. Res. 2020 48 3 0300060519887276 10.1177/0300060519887276 31847652
    [Google Scholar]
  19. Zhao J. Zhang X. Gong C. Zhang J. Targeted therapy with apatinib in a patient with relapsed small cell lung cancer. Medicine 2017 96 50 e9259 10.1097/MD.0000000000009259 29390367
    [Google Scholar]
  20. Liu M. Qiu G. Guan W. Xie X. Lin X. Xie Z. Zhang J. Qin Y. Du H. Chen X. Deng Y. Li S. Zhong N. Zhou C. Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A multicenter, single-arm trial. Signal Transduct. Target. Ther. 2025 10 1 65 10.1038/s41392‑025‑02153‑7 39962074
    [Google Scholar]
  21. Chakraborty S. Sridhar S. Ventura K. Sritharan R. Tocheva A. Sen T. Protocol to co-culture SCLC cells with human CD8+ T cells to measure tumor cell killing and T cell activation. STAR Protoc. 2025 6 2 103767 10.1016/j.xpro.2025.103767 40232937
    [Google Scholar]
  22. Huang W. Fu B. Xu H. β-elemene inhibits tumor-promoting in small cell lung cancer by affecting M2 macrophages and TGF-β. BMC Pulm. Med. 2025 25 1 97 10.1186/s12890‑025‑03533‑z 40022030
    [Google Scholar]
  23. Kobayashi T. Mitsuhashi A. Hongying P. Shioya M. Kojima K. Nishikimi K. Yahiro K. Shozu M. Bexarotene-induced cell death in ovarian cancer cells through Caspase-4-gasdermin E mediated pyroptosis. Sci. Rep. 2022 12 1 11123 10.1038/s41598‑022‑15348‑7 35778597
    [Google Scholar]
  24. Liu T. Guan Y. Bai L. Ni B. Zhang H. Zhang Y. Gu J. Aimaiti M. Wang S. Yue B. Zhang Z. Xia X. Clinical study of adebrelimab in combination with apatinib and irinotecan for PD-1 inhibitor-ineffective advanced-stage gastric cancer: Study protocol for a single-arm, single-centre, exploratory trial. BMJ Open 2025 15 6 e089286 10.1136/bmjopen‑2024‑089286 40467306
    [Google Scholar]
  25. Sen T. Rodriguez B.L. Chen L. Corte C.M.D. Morikawa N. Fujimoto J. Cristea S. Nguyen T. Diao L. Li L. Fan Y. Yang Y. Wang J. Glisson B.S. Wistuba I.I. Sage J. Heymach J.V. Gibbons D.L. Byers L.A. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 2019 9 5 646 661 10.1158/2159‑8290.CD‑18‑1020 30777870
    [Google Scholar]
  26. Fan Z. Wu C. Chen M. Jiang Y. Wu Y. Mao R. Fan Y. The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation. Acta Pharm. Sin. B 2022 12 3 1041 1053 10.1016/j.apsb.2021.09.010 35530130
    [Google Scholar]
  27. Hong H. Su J. Huang C. Lu X. Cui Z. Comprehensive insights into the function and molecular and pharmacological regulation of neuron-derived orphan receptor 1, an orphan receptor. Front. Pharmacol. 2022 13 981490 10.3389/fphar.2022.981490 36110555
    [Google Scholar]
  28. Ma J. Hua L. Zhu Y. Mao G. Fu C. Qin S. Photo-thermally controllable tumor metabolic modulation to assist T cell activation for boosting immunotherapy. Int. J. Nanomedicine 2024 19 11181 11194 10.2147/IJN.S483815 39513087
    [Google Scholar]
  29. Fang C. Wu Y. Wu Y. Guo Q. Wu J. Ke G. Jia M. Zhu J. The effectiveness of anti-PD-L1 treatment and the underlying regulatory mechanism in ovarian clear cell carcinoma. Int. Immunopharmacol. 2025 164 115344 10.1016/j.intimp.2025.115344 40803218
    [Google Scholar]
  30. Lan Y. Gu Q. Feng Y. Curculigoside mediates the STAT3/PD-L1 pathway to inhibit the proliferation, invasion, and immune escape of breast cancer cells. Int. Immunopharmacol. 2025 167 115668 10.1016/j.intimp.2025.115668 41135479
    [Google Scholar]
  31. Yu H. Boyle T.A. Zhou C. Rimm D.L. Hirsch F.R. PD-L1 expression in lung cancer. J. Thorac. Oncol. 2016 11 7 964 975 10.1016/j.jtho.2016.04.014
    [Google Scholar]
  32. Geng Q. Xu J. Du C. Zhang D. Jin Y. Song J. Qu W. Zhang C. Su G. Jiao P. Small molecules targeting immune checkpoint proteins for cancer immunotherapy: A patent and literature review (2020–2024). Expert Opin. Ther. Pat. 2025 35 4 409 440 10.1080/13543776.2025.2462849 39907457
    [Google Scholar]
  33. Cheng P. He J. Cheng P. Chen K. Zhao G. Progress of research on PD-L1 inhibitor adebrelimab usage in malignant tumors. Front. Oncol. 2024 14 1468569 10.3389/fonc.2024.1468569 39687879
    [Google Scholar]
  34. Zhao S. Ren S. Jiang T. Zhu B. Li X. Zhao C. Jia Y. Shi J. Zhang L. Liu X. Qiao M. Chen X. Su C. Yu H. Zhou C. Zhang J. Camidge D.R. Hirsch F.R. Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer. Cancer Immunol. Res. 2019 7 4 630 643 10.1158/2326‑6066.CIR‑17‑0640 30755403
    [Google Scholar]
  35. Zhang Y. Wang F. Sun H. Huang Y. Gao J. Huang H. Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer. J. Cancer Res. Clin. Oncol. 2021 147 8 2209 2222 10.1007/s00432‑021‑03633‑3 33891173
    [Google Scholar]
  36. Wen S. Shao G. Zheng J. Zeng H. Luo J. Gu D. Apatinib regulates the cell proliferation and apoptosis of liver cancer by regulation of VEGFR2/STAT3 signaling. Pathol. Res. Pract. 2019 215 4 816 821 10.1016/j.prp.2019.01.021 30686547
    [Google Scholar]
  37. Long Y. Wang Z. Fan J. Yuan L. Tong C. Zhao Y. Liu B. A hybrid membrane coating nanodrug system against gastric cancer via the VEGFR2/STAT3 signaling pathway. J. Mater. Chem. B Mater. Biol. Med. 2021 9 18 3838 3855 10.1039/D1TB00029B 33908580
    [Google Scholar]
  38. Yang B. Kuai F. Chen Z. Fu D. Liu J. Wu Y. Zhong J. miR-634 decreases the radioresistance of human breast cancer cells by targeting STAT3. Cancer Biother. Radiopharm. 2020 35 3 241 248 10.1089/cbr.2019.3220 32077744
    [Google Scholar]
  39. Zhang X. Zhang X. Ge X. Liu M. Mangiferin prevents hepatocyte epithelial-mesenchymal transition in liver fibrosis via targeting HSP27-mediated JAK2/STAT3 and TGF-β1/Smad pathway. Phytother. Res. 2022 36 11 4167 4182 10.1002/ptr.7549 35778992
    [Google Scholar]
  40. Peng Q.X. Han Y.W. Zhang Y.L. Hu J. Fan J. Fu S.Z. Xu S. Wan Q. Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma. Oncotarget 2017 8 32 52813 52822 10.18632/oncotarget.17264 28881773
    [Google Scholar]
  41. Zhong N. Zhuang W. Huang Q. Wang Q. Jin W. Apatinib inhibits the growth of small cell lung cancer via a mechanism mediated by VEGF, PI3K/Akt and Ki-67/CD31. J. Cell. Mol. Med. 2021 25 21 10039 10048 10.1111/jcmm.16926 34590406
    [Google Scholar]
  42. Xie C. Zhou X. Liang C. Li X. Ge M. Chen Y. Yin J. Zhu J. Zhong C. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer. J. Exp. Clin. Cancer Res. 2021 40 1 266 10.1186/s13046‑021‑02069‑4 34429133
    [Google Scholar]
  43. Gao C. Chen L. Zhao L. Su Y. Ma M. Zhang W. Hong X. Xiao L. Xu B. Hu T. Apatinib degrades PD-L1 and reconstitutes colon cancer microenvironment via the regulation of myoferlin. Cancers 2025 17 3 524 10.3390/cancers17030524 39941891
    [Google Scholar]
/content/journals/cmc/10.2174/0109298673478917260414214002
Loading
Apatinib and Adebrelimab Exhibit Synergistic Antitumor effects in Small Cell Lung Cancer: An In Vitro Study
Bentham Science Publishers ; https://doi.org/10.2174/0109298673478917260414214002
/content/journals/cmc/10.2174/0109298673478917260414214002
/content/journals/cmc/10.2174/0109298673478917260414214002
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download
file format download Download

  • Article Type:     Research Article
Keywords: PD-L1 ; Adebrelimab ; SCLC ; CD8+ T cells ; Apatinib ; VEGFR2/STAT3

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test